Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America.
The last earnings update was 46 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Sintx Technologies. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Sintx Technologies's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sintx Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Sintx Technologies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Sintx Technologies's earnings growth to the United States of America market average as no estimate data is available.
Unable to compare Sintx Technologies's revenue growth to the United States of America market average as no estimate data is available.
Unable to determine if Sintx Technologies is high growth as no earnings estimate data is available.
Unable to determine if Sintx Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Sintx Technologies's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Sintx Technologies's finances.
The net worth of a company is the difference between its assets and liabilities.
Sintx Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Sintx Technologies's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Sintx Technologies's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Sintx Technologies has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. B. Sonny Bal, M.D., J.D., MBA, PhD, has been the Chief Executive Officer and President of Sintx Technologies, Inc. (formerly known as Amedica Corporation) since October 2014 and its Chairman since August 21, 2014. Dr. Bal serves as Principal Financial Officer at Sintx Technologies, Inc. (formerly known as Amedica Corporation). Dr. Bal serves as an Assistant Professor of Orthopaedic Surgery at the University of Missouri, Columbia, specializing in hip and knee replacement surgery. Dr. Bal is Professor & Chief of Adult Reconstruction at the University of Missouri, Columbia. He also is an Adjunct Professor of Material Sciences at the University of Missouri at Rolla. Dr. Bal has been a Director of Sintx Technologies, Inc. (formerly known as Amedica Corporation) since February 8, 2012. Dr. Bal received his M.D. degree from Cornell University and an M.B.A. from Northwestern University, a J.D. from the University of Missouri, a Ph.D. in Engineering from the Kyoto Institute of Technology in Japan and is a member of the American Academy of Orthopaedic Surgeons and the American Association of Hip and Knee Surgeons and the International Society of Technology in Arthroplasty. Dr. Bal is a licensed attorney and co-founder of the Bal Brenner law firm in North Carolina.
B.'s compensation has been consistent with company performance over the past year.
B.'s remuneration is about average for companies of similar size in United States of America.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Sintx Technologies management team is about average.
Chief Scientific Officer
GM & VP Operations
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Sintx Technologies board of directors is about average.
Sintx Technologies, Inc., a biomaterial company, researches, develops, manufactures, and commercializes a range of medical implant products manufactured with silicon nitride in the United States, Europe, and South America. The company offers ceramic based biomaterial solutions in various medical and industrial applications. It provides spine implant products under the Valeo brand to surgeons and hospitals for use in cervical and thoracolumbar spine surgery. The company markets and sells its products directly; and through direct sales organizations, distributors, as well as original equipment manufacturer and private label partnerships. The company was formerly known as Amedica Corporation and changed its name to Sintx Technologies, Inc. in October 2018. Sintx Technologies, Inc. was founded in 1996 and is headquartered in Salt Lake City, Utah.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.